Skip to main content
No access
21st-Century Psychiatrist
Published Online: 15 October 2024

Renal Impairment and Dose Adjustment of Long-Acting Injectable Antipsychotics: Are We Getting It Right? A Case Report

Abstract

Renal impairment is defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 with or without kidney damage. Creatinine, which is found in serum and urine, is a common biomarker to estimate renal function and is used in most eGFR equations. Renal impairment can decrease or increase drug effects, necessitating therapeutic adjustments. Increased effect is related to drug accumulation that leads to increased elimination time and potential toxicity. eGFR plays a crucial role in drug dosing, particularly for renally excreted medications. However, the lack of recognition of pre-existing renal impairment and the incorrect interpretation of eGFR equations remain challenges. This case report explores the significance of eGFR in patients with psychiatric conditions, especially in the context of long-acting antipsychotic drug dosing.

Get full access to this content

View all available purchase options and get full access to this content.

Information & Authors

Information

Published In

History

Published in print: Fall 2024
Published online: 15 October 2024

Keywords

  1. Antipsychotics
  2. long-acting injectables
  3. Education
  4. renal impairment
  5. dose adjustments
  6. case report

Authors

Details

Colette Raphaël, B.Pharm., M.H.A. [email protected]
Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Gary Remington, M.D., Ph.D.
Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Ofer Agid, M.D.
Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Notes

Send correspondence to Ms. Raphaël ([email protected]).

Competing Interests

Dr. Remington receives research support from the Canadian Institutes of Health Research; HLS Therapeutics, Inc.; and the University of Toronto. Dr. Agid is an advisory board member and consultant for Allergan/AbbVie, Janssen-Ortho (Johnson & Johnson), Lundbeck, Mylan/Viatris, Otsuka, and Teva. He has had speaking engagements for Allergan/AbbVie; HLS Therapeutics, Inc.; Janssen-Ortho (Johnson & Johnson); Lundbeck; Medscape; Mylan/Viatris; and Otsuka; and he has research contracts with Boehringer Ingelheim, DiaMentis, Janssen-Ortho (Johnson & Johnson), Lundbeck, Neurocrine Bioscience, and Otsuka. Ms. Raphaël reports no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share